nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

24.02.2017 | Letter to the Editor

Monitoring metastatic lesions in TENIS, initiating multi-targeted tyrosine kinase inhibitors and follow-up: should the newer FDG PET-CT quantitative indices be the defining objective parameter in clinical trials?

verfasst von: Sandip Basu, Ashwini Kalshetty

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 6/2017

Einloggen, um Zugang zu erhalten

Excerpt

Dear Editor, …

Silberstein EB. The problem of the patient with thyroglobulin elevation but negative iodine scintigraphy: the TENIS syndrome. Semin Nucl Med. 2011;41(2):113–20.CrossRefPubMed

Basu S, Dandekar M, Joshi A, D’Cruz A. Defining a rational step-care algorithm for managing thyroid carcinoma patients with elevated thyroglobulin and negative on radioiodine scintigraphy (TENIS): considerations and challenges towards developing an appropriate roadmap. Eur J Nucl Med Mol Imaging. 2015;42(8):1167–71.CrossRefPubMed

Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26(1):1–133.CrossRefPubMedPubMedCentral

Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015;372(7):621.CrossRefPubMed

Brose MS, Nutting CM, Jarzab B, Elisei R, Siena S, Bastholt L, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Decision Investig Lancet. 2014;384(9940):319–28.CrossRef

Titel: Monitoring metastatic lesions in TENIS, initiating multi-targeted tyrosine kinase inhibitors and follow-up: should the newer FDG PET-CT quantitative indices be the defining objective parameter in clinical trials?
verfasst von: Sandip Basu
Ashwini Kalshetty
Publikationsdatum: 24.02.2017
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 6/2017
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-017-3648-x

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2017

68Ga-PSMA-11 PET/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour

In memoriam Professor Jan van der Schoot (1927–2017)

Refining prognosis in patients with hepatocellular carcinoma through incorporation of metabolic imaging biomarkers

PET imaging of α7 nicotinic acetylcholine receptors: a comparative study of [18F]ASEM and [18F]DBT-10 in nonhuman primates, and further evaluation of [18F]ASEM in humans

Central noradrenaline transporter availability in highly obese, non-depressed individuals

Measuring the actual I-131 thyroid uptake curve with a collar detector system: a feasibility study